On March 15, 2022 Coherus BioSciences, Inc. (Nasdaq: "CHRS", "the Company", "Coherus") reported Rosh Dias, MD, MRCP, has been appointed Chief Medical Officer. Dr. Dias will serve as a member of the Company’s executive leadership team and oversee a number of clinical functions including medical affairs, clinical operations, pharmacovigilance and clinical development (Press release, Coherus Biosciences, MAR 15, 2022, View Source [SID1234610115]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Rosh is a terrific addition to Coherus at a time when we are sharply focused on successful execution of new product launches and on the advancement of our immuno-oncology development pipeline," said Denny Lanfear, CEO of Coherus. "A seasoned pharmaceutical executive with a demonstrated record of success leading medical affairs across multiple therapeutic areas, including oncology, he brings important experience and expertise as we prepare for the launch of up to four new products over the next 18 months."
"I am excited to join Coherus at this pivotal moment when the Company is preparing for the launch of multiple new products in immuno-oncology, immunology and ophthalmology," said Dr. Dias. "With toripalimab and its clinical and pre-clinical pipeline of PD-1 combination candidates, Coherus is well positioned to become a leader in innovative immuno-oncology drug development and commercialization. I am very excited about Coherus’ work advancing these novel treatments and about the possibilities to impact and help patients with cancer across multiple tumor types."
Dr. Dias brings more than 20 years of pharmaceutical and biotechnology industry experience leading United States and global teams in clinical development and medical affairs across multiple disease areas including oncology, cardiometabolic health and rare diseases. Dr. Dias joins Coherus most recently from Spruce Biosciences, Inc., where he was the Chief Medical Officer overseeing global clinical development and strategy. Prior to Spruce, he served as Chief Medical Officer at Indivior PLC, a global commercial pharmaceutical company focused on substance abuse and other serious mental disorders. From 2014 to 2018, Dr. Dias held senior leadership positions at Amgen, Inc., most recently as Vice President, Global Scientific Affairs, and at Amgen’s subsidiary, Onxy Pharmaceuticals, Inc., as Head of Global Medical and Scientific Affairs. Prior to Onyx, Dr. Dias worked for 10 years at Novartis Oncology in roles of increasing responsibility, including leadership roles in the global organization, the United States and in Australia, where he directed clinical development and medical affairs efforts with a focus on oncology, hematology and rare diseases.
Dr. Dias holds a Medical Doctor degree from Charing Cross and Westminster Medical School in the UK, and is a Member of the Royal College of Physicians through postgraduate qualification in Internal Medicine.